12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Nintedanib: Phase III data

The double-blind, international Phase III LUME-Lung 1 trial in 1,314 patients with locally advanced or metastatic stage IIIb/IV or recurrent NSCLC after failure of first-line chemotherapy showed that second-line treatment with twice-daily 200 mg nintedanib plus docetaxel met the primary endpoint of improving median PFS vs. placebo plus docetaxel (3.4 vs. 2.7 months, p=0.0019). Nintedanib plus docetaxel missed the secondary endpoint of improving median OS vs....

Read the full 308 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >